March 31, 2016
Earlier this year, Allergan announced its acquisition of Anterios, Inc., a clinical stage biopharmaceutical company developing a topical Botox. With the acquisition comes the worldwide rights to ANT-1207, a topical formulation of botulinum toxin, which is being developed for the treatment of crow’s feet lines, acne, and hyperhidrosis (excessive sweating).
“The acquisition of Anterios bolsters Allergan’s commitment to innovation and maintaining its leadership position in neurotoxin development and commercialization,” said Executive VP and President of Global Brands Research & Development at Allergan. “Our team at Allergan pioneered the development and commercialization of Botox, the market-leading neurotixn used in both medical aesthetics and therapeutic areas of medicine. This acquisition demonstrates our ability to apply our tremendous scientific leadership in neurotoxins to further extend our already deep neurotoxin pipeline by advancing a new delivery system and formulations that are appealing to both patients and physicians.”
Here at Utah Facial Plastics, having an additional delivery option for Botox is an exciting notion. For patients highly adverse to injections, a topical form of a neuromodulator would be highly beneficial if outcomes prove to be as successful as they are with the injectable form.
Allergan also continues to study additional benefits of botulinum toxin and is currently analyzing the efficacy of Botox treatments for Depression as well as osteoarthritis.
As a top Botox provider in the state of Utah, we will continue to follow these exciting developments and expand our product line to better serve our patients in the best way possible.
For more information on Botox, Click HERE or call (801)776-2220.
Tags: allergan, anterios, botox, injectable, topical botox
This post was written by Jenny Yergensen